Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.
Nicolas MartinNicolas IsambertCarlos Gomez-RocaRainer-Georg GoeldnerSylvie ZanettaBehbood SadrolhefaziHélène de Mont-SerratMario CamponeJean-Pierre DelordPublished in: Cancer chemotherapy and pharmacology (2018)
Despite optimal management of diarrhea including treatment of grade I symptoms, it was not possible to treat the patients above a dose of 20 mg of afatinib daily in combination with 3-weekly trastuzumab. The MTD of afatinib in combination with the recommended 3-weekly dose of trastuzumab was 20 mg daily.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- tyrosine kinase
- end stage renal disease
- metastatic breast cancer
- newly diagnosed
- chronic kidney disease
- squamous cell carcinoma
- physical activity
- small cell lung cancer
- clinical trial
- prognostic factors
- study protocol
- papillary thyroid
- randomized controlled trial
- patient reported outcomes
- combination therapy
- open label
- patient reported